Fresh Hope for Those With Chronic Graft vs Host Disease (GvHD)
Fresh Hope for Those With Chronic Graft vs Host Disease (GvHD)
Posted Jul 28, 2021

Chronic graft versus host disease (cGvHD) is a complication that can occur in about 50% of patients following allogeneic stem cell transplant. Most cases are mild to moderate, but about 10-15 % of patients develop symptoms that are more severe with significant morbidity and mortality.

“In cGvHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are living with cGvHD.”

Patients are typically systemically treated for this debilitating disease with corticosteroids and calcineurin inhibitors (such as cyclosporin and tacrolimus).

Belumosudil (Rezurock) Receives Breakthrough Therapy Designation

The news that the US Food and Drug Administration approved the compound belumosudil (future brand name: Rezurock) on July 16, 2021 and designated the drug as a Breakthrough Therapy, will therefore be welcomed by those patients with chronic GvHD. The drug is approved for “the treatment of adult and pediatric patients 12 years and older with cGvHD after failure of at least two prior lines of systemic therapy.” The compound is an oral drug that is the first in a new class of compounds targeting Rho-associated coiled-coil kinase 2 (ROCK2), a pathway that modulates the inflammatory response.

The drug’s developer, Kadmon, completed 2 Phase II clinical studies of about 65 patients each that were dosed either with 200 mg once a day or 200 mg taken twice a day.

The median time from cGvHD diagnosis was 25.3 months and 48% of patients had four or more organs involved. Patients had cycled through a median of 3 prior lines of systemic therapy and 78% were refractory to their last therapy.

In other words, this patient population was in serious need of a treatment alternative.

The results of these two studies can be summarized as follows:

  • Overall Response Rates (ORR) of 74% with 200 mg once daily and 77% with 200 mg twice daily
  • Responses were achieved across patient subgroups and complete responses were observed in all organ systems, including the lungs. Responses were durable, with a median duration of 54 weeks, which represents the total combined response periods for each patient.
  • 44% of responders maintained their response for ≥1 year.
  • There was a clinically meaningful improvement from baseline in the Lee Symptom Scale (LSS) score, a chronic GvHD symptom measurement, with belumosudil that was observed in 61% of patients.
  • During treatment, 65% of patients were able to reduce their corticosteroid dose, with 21% of patients completely discontinuing corticosteroid therapy. Additionally, 22% of patients completely discontinued their calcineurin inhibitor therapy.
  • Belumosudil was well-tolerated and adverse events have been consistent with those expected in patients with advanced cGvHD receiving corticosteroids and/or other immunosuppressants.
  • Kadmon has announced that the drug will be commercially available by late August 2021. This is, unquestionably, good news for those living with this tough to treat/manage disease.
The author Paul Kleutghen

about the author
Paul Kleutghen

I was diagnosed in 2014 with blood cancer and have been very fortunate to find treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and a grandson who is the ‘light of my life’. Successful treatment has allowed Vicki and I to do what we love best: traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs and, very specifically, CAR-T therapies, with recent contributions posted by Health Affairs, the Institute for Clinical and Economic Review and the Centers for Medicare and Medicaid Services.

More AML News Articles

Article Image The Power of Personalized Medicine to Treat Your Acute Myeloid Leukemia with Dr. Stein, Oct 28th @ 2 PM Central Article Image Moving Toward A Personalized Medicine Approach for Treating AML Article Image FDA Approval Update: Jakafi Approved for Chronic Graft vs Host Disease

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Follow Us

facebook instagram twitter youtube


Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect


Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811